- Home
- Test Categories
- Allergy Testing
- Autoimmune Diseases
- Blood and Blood Diseases
- Cancer Detection
- Diabetes
- DNA, Paternity and Genetic Testing
- Drug Screening
- Environmental Toxin Testing
- Female Specific Tests
- Fitness, Nutrition and Anti-Aging
- Gastrointestinal Diseases
- General Wellness
- Heart Health and Cholesterol
- Hormones and Metabolism
- Immunization Check
- Infectious Diseases
- Infertility Testing
- Kidney Diseases
- Liver Diseases
- Male Specific Tests
- Musculoskeletal Diseases
- Sexually Transmitted Diseases (STD's)
- Therapeutic Drug Monitoring
- Thyroid Diseases
- - STD Testing
- About STD Testing
- Chlamydia and Gonorrhea Test
- Cytomegalovirus (CMV) Antibodies, IgG
- Cytomegalovirus (CMV) Antibodies, IgM, Quantitative
- Epididymitis Screen
- Hepatitis A and B Immune Status Profile Test
- Hepatitis A and B Profile, Acute Diagnostic
- Hepatitis A and B Profile, Comprehensive
- Hepatitis A Antibody, IgM
- Hepatitis A Antibody, Total
- Hepatitis A Profile, Acute verses Chronic Differentiation
- Hepatitis B and C Profile Test (Comprehensive)
- Hepatitis B Core Antibody, IgG, IgM, Differentiation
- Hepatitis B Core Antibody, IgM
- Hepatitis B Core Antibody, Total
- Hepatitis B Patient Management Profile Test
- Hepatitis B Profile
- Hepatitis B Surface Antibody Test
- Hepatitis C Antibody Test
- Hepatitis C Virus (HCV) Antibody, With Reflex to RIBA
- Hepatitis C Virus (HCV), RNA PCR, Qualitative
- Hepatitis Panel, Acute
- Hepatitis Profile II (Diagnostic Follow-up)
- Herpes Simplex Virus (HSV) Type I and II IgG
- Herpes Simplex Virus (HSV) Type II IgG
- Herpes Simplex Virus (HSV), Type I and II IgM
- HIV-1 and HIV-2 Screen
- HIV-1 Antibodies Test
- HIV-1 DNA RT- PCR With HIV Antibodies , ICMA
- HIV-2 Antibodies
- Human Immunodeficiency Virus 1 (HIV-1) RNA (bDNA)
- Human Immunodeficiency Virus 2 (HIV-2), Qualitative, PCR
- Mycoplasma/Ureaplasma, Real-Time PCR
- Soluble Liver Antigen (SLA) IgG Antibody (Autoimmune Hepatitis)
- STD Recent Exposure Panel
- STD Urinary Tract Infection Panel
- Syphilis (RPR) Test
- Treponema pallidum Antibodies (TP-PA)
- Ultimate STD Panel
- Ultimate Viral STD Panel
- See All STD Tests
- - Blood Tests
- Allergy Testing
- Autoimmune Disease Testing
- Blood Disorder and Blood Disease Testing
- Cancer Detection Testing
- Diabetes Testing
- DNA, Paternity and Genetic Testing
- Drug Screening Testing
- Environmental Testing
- Female-Specific Testing
- Fitness, Nutrition and Anti-Aging Testing
- Gastrointestinal Disease Testing
- General Wellness Testing
- Heart Health and Cholesterol Testing
- Hormone Blood Tests
- Immunization Testing
- Infectious Disease Testing
- Infertility Testing
- Kidney Disease Testing
- Liver Function Tests
- Musculoskeletal Disorders Testing
- Prostate Testing
- Therapeutic Drug Monitoring Testing
- Thyroid Testing
- - All Tests
- Lab Locations
- Why Online Lab Tests
- How it Works
- About Us
- FAQ
- Health Resources
Questions?
1.877.283.7882
1.877.283.7882
Private MD News
Home | News | Cancer Detection and Tumor MarkersClinical testing of new cancer drug a success, according to study
Updated: 2010-01-18 23:16:50 CST Category: Cancer Detection and Tumor Markers
by Alex Schoenfeld
Recent phase 2 testing of the drug known as ASA404, or vadimezan, has shown significant promise in patients suffering from non-small cell lung cancer (NSCLC).
Vadimezan is an anti-angiogenesis agent that contains a mechanism which chokes off a tumor's blood supply. It is designed to benefit patients with either squamous or non-squamous NSCLC.
There currently are other anti-angiogenesis drugs on the market, but they are commonly associated with side-effects such as interference with the formation of new blood vessels.
"Standard chemotherapy is currently the mainstay of treatment for patients with squamous NSCLC," said lead researcher Mark McKeage.
"New targeted therapies and chemotherapies have been evaluated, but many show little promise as first-line treatments in patients with this type of cancer," he added.
In the study, McKeage and his colleagues found that the overall survival rate was significantly higher in patients treated with vadimezan compared to respondents undergoing chemotherapy alone.
Moreover, the testing of vadimezan did not show any adverse side-effects nor did it appear to increase toxicity levels in patients. 
Related Articles from Private MD:
-
PET-CT tests may help identify hidden cancers
-
Having relatives with pancreatic cancer leads to increased risk
-
Blood test may aid doctors in lung cancer diagnosis
-
Children who survive cancer have high risk of heart disease, new study find
-
Skin cancer diagnosed earlier, more frequently in whites
Subscribe to Private MD Health News RSS Feed: 
News Categories:
Advanced Lipid Treatment I Allergy Testing Anemia and RBC disorders Autoimmune Diseases Bariatric Lab Testing Blood and Blood Diseases Breast Cancer Detection and Tumor Markers Celiac Disease Testing Chlamydia Coagulation and blood clotting disorders Colon Diabetes DNA, Paternity and Genetic testing Drug Screening Environmental Toxin Testing Female Specific Tests Gastrointestinal Diseases General Health General Wellness Heart Health and Cholesterol Herpes HIV HIV monitoring/Treatment/Testing/Post Diagnos Hormones and Metabolism Infectious Diseases Infertility Testing-Male Infertitlity Hormone Testing Kidney Diseases Leukemia and WBC disorders Liver Liver Diseases Lyme Disease Male Specific Tests Menopause/Peri-Menopausal Diagnosis Organ Specific Testing Ovarian Prostate Sexually Transmitted Diseases Thyroid Diseases Vitamin D Deficiency-Diagnosis and Treatment
Visit the Health News Archive: Click Here
Questions about online blood testing or how to order a lab test? Click here to get started or call us toll-free at 1.877.283.7882. Our certified professionals are ready to assist you.
